Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DRP-104 and Durvalumab in Advanced Fibrolamellar Hepatocellular Carcinoma
NCT06027086Phase 2Active, not recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Feb 2024
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sirpiglenastat in fibrolamellar hepatocellular carcinoma (FLHCC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Number of participants experiencing drug-related adverse events (AEs) requiring treatment discontinuation at 4 years and Objective Response Rate at 4 years. Started Feb 2024; status: active, not recruiting.
02
Drugs
sirpiglenastat
03
Conditions
fibrolamellar hepatocellular carcinoma (FLHCC)
Beyond the preview
Go deeper on NCT06027086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06027086.